US 11,858,958 B2
Blank liposome with ginsenoside Rg3 or its analog as membrane materials and preparations and uses thereof
Jianxin Wang, Shanghai (CN); Chao Hong, Shanghai (CN); Ying Zhu, Shanghai (CN); Jiaxuan Xia, Shanghai (CN); Dan Wang, Shanghai (CN); Yingjiang Chen, Shanghai (CN); and Huaxing Zhan, Shanghai (CN)
Assigned to Shanghai Ginsome Pharmatech Co., Ltd., Shanghai (CN)
Appl. No. 16/961,899
Filed by Shanghai Ginsome Pharmatech Co., Ltd., Shanghai (CN)
PCT Filed Nov. 29, 2019, PCT No. PCT/CN2019/121880
§ 371(c)(1), (2) Date Jul. 13, 2020,
PCT Pub. No. WO2020/108600, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 201811447243.4 (CN), filed on Nov. 29, 2018.
Prior Publication US 2020/0369714 A1, Nov. 26, 2020
Int. Cl. C07J 17/00 (2006.01); A61P 35/00 (2006.01); A61K 9/127 (2006.01); A61K 47/28 (2006.01); A61K 45/06 (2006.01); C07B 63/04 (2006.01)
CPC C07J 17/005 (2013.01) [A61K 9/1277 (2013.01); A61K 47/28 (2013.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01); C07B 63/04 (2013.01)] 28 Claims
 
1. A blank liposome having a membrane, wherein the membrane comprises a lipid and a ginsenoside of Formula I:

OG Complex Work Unit Chemistry
wherein,
“*” represents a chiral carbon;
R1 is H, R10, R11 or hydroxy (OH);
R10 is selected from the group consisting of: —O-Glc, —O-Rha, —O-Lyx, —O-Xyl, —O-Ara(p), —O-Ara(f), —O-Glc(2→1)Glc, —O-Glc(6→1)Glc, —O-Glc(2→1)Rha, —O-Glc(2→1)Xyl, —O-Glc(6→1)Xyl, —O-Glc(6→1)Rha, —O-Glc(2→1)Ara(p), —O-Glc(6→1)Ara(p), —O-Glc(2→1)Ara(f), —O-Glc(6→1)Ara(f), —O-Glc(2→1)Glc(2→1)Glc, —O-Glc(2→1)Glc(2→1)Xyl, —O-Glc(6→1)Glc(6→1)Xyl, —O-Glc(2→1)Glc(4→1)Xyl, —O-Glc(2→1)Lyx, —O-Glc(6→1)Lyx, —O-Glc(2→1)Glc(2→1)Rha, —O-Glc(2→1)Glc(2→1)Lyx, —O-Glc(2→1)Glc(2→1)Ara(f), —O-Glc(2→1)Glc(2→1)Ara(p), —O-Glc(2→1)Glc(6→1)Glc, —O-Glc(2→1)Glc(6→1)Rha, —O-Glc(2→1)Glc(6→1)Xyl, —O-Glc(2→1)Glc(6→1)Lyx, —O-Glc(2→1)Glc(6→1)Ara(f), —O-Glc(2→1)Glc(6→1)Ara(p), —O-Glc(6→1)Glc(2→1)Glc, —O-Glc(6→1)Glc(2→1)Rha, —O-Glc(6→1)Glc(2→1)Xyl, —O-Glc(6→1)Glc(2→1)Lyx, —O-Glc(6→1)Glc(2→1)Ara(f), —O-Glc(6→1)Glc(2→1)Ara(p), —O-Glc(6→1)Glc(6→1)Glc, —O-Glc(6→1)Glc(6→1)Rha, —O-Glc(6→1)Glc(6→1)Lyx, —O-Glc(6→1)Glc(6→1)Ara(f) and —O-Glc(6→1)Glc(6→1)Ara(p); wherein Glc is glucopyranosyl, Xyl is xylopyranosyl, Rha is Rhamnopyranosyl, Ara(p) is arabinopyranosyl, Ara(f) is arabinofuranosyl, Lyx is Lyxosyl; number indicates carbon position, arrow (4) indicates the connection relationship, and the same hereinafter;
R11 is a group formed by replacing one or more OH groups in R10 with R10, and each of the one or more than one R10 groups is independently the same as or different from each other.